Artificial Intelligence Identifies Lung Cancer Patients at Risk of Harm Caused by Immunotherapy

Artificial Intelligence Identifies Lung Cancer Patients at Risk of Harm Caused by Immunotherapy
February 9, 2021
In a subset of patients diagnosed with non-small cell lung cancer (NSCLC), immunotherapy paradoxically exacerbates tumor growth and significantly shortens survival. Currently there are no clinically validated biomarkers that can identify patients at risk of this paradoxical response called “hyperprogression.”
Using artificial intelligence (AI) analysis of simple tissue scans, researchers at Case Western University claim they have discovered biomarkers that could tell which lung cancer patients might get worse from immunotherapy.
In addition to those who would benefit from immunotherapy, and those who might not, researchers and oncologists can now identify a third category of patients called hyper-progressors who would be harmed by the same immunotherapy, says Pranjal Vaidya, a PhD student in biomedical engineering and researcher at the university’s Center for Computational Imaging and Personalized Diagnostics (CCIPD).

Related Keywords

Pradnya Patil ,Anant Madabhushi ,Pranjal Vaidya ,Donnell Institute Professor Of Biomedical Engineering ,National Cancer Institute ,Taussig Cancer Institute ,Case Western University ,Computational Imaging ,Personalized Diagnostics ,National Cancer ,Donnell Institute Professor ,Biomedical Engineering ,Cleveland Clinic ,பிரட்ஞய பாட்டீல் ,பிரஞ்சள் வைத்யா ,டோனெல் நிறுவனம் ப்ரொஃபெஸர் ஆஃப் உயிர் மருத்துவ பொறியியல் ,தேசிய புற்றுநோய் நிறுவனம் ,வழக்கு மேற்கு பல்கலைக்கழகம் ,கணக்கீட்டு இமேஜிங் ,தனிப்பயனாக்கப்பட்டது பரிசோதனை ,தேசிய புற்றுநோய் ,டோனெல் நிறுவனம் ப்ரொஃபெஸர் ,உயிர் மருத்துவ பொறியியல் ,கிளீவ்லேண்ட் சிகிச்சையகம் ,